Acute lymphoblastic leukemia is highly sensitive to induction chemotherapy; however, long-term survival in adults has been less than 35%, primarily as a result of high relapse rate. Treatment for relapsed disease is even less successful. The optimal post-remission therapy in the first complete remission offers the best opportunity for leukemia-free survival. Allogeneic donor stem cell transplantation can offer a unique anti-leukemia effect and a potential for extended survival. We will discuss advances in unrelated donor (URD) stem cells transplantation, improvements in transplantation process and supportive care along with growing experience with umbilical cord blood (UCB) allografts.
Introduction
In the treatment of ALL, achieving a CR to induction therapy is indispensable for a favorable outcome but due to recurrent disease, only one-third of patients survive 5 years. The key to durable leukemia-free survival (LFS) is to prevent relapse with safe and well-tolerated post-remission treatment. Clinical options include a choice of prolonged intensification, consolidation and maintenance chemotherapy, high-dose chemo/radiotherapy with autologous stem cell rescue or allogeneic donor hematopoietic cell transplantation (HCT). While all can improve survival, the optimal strategy is still undefined.
Features of high-risk ALL include age above 35 years, elevated WBC at diagnosis (430 000 for B-cell ALL and 4100 000 for T-cell ALL), presence of Ph þ and slow response to induction (no CR within 28 days). Additional identified adverse features are t(4;11) and mature B-cell immunophenotype. These are all associated with greater risk of relapse. HLA-matched sibling allogeneic HCT offers a good chance of extensive LFS for patients with high-risk ALL in first or later CR. Since only one-third of patients have a matched sibling donor, other graft alternatives have to be considered including autologous transplant (auto), unrelated donor (URD) marrow or filgrastim-mobilized peripheral blood, umbilical cord blood (UCB) and haploidentical-related donors. Although treatment-related mortality (TRM) with autografting is low, generally less than 5%, the overall survival (OS) is disappointing due to unacceptably high risk of relapse. Enthusiasm for autologous HCT has dwindled in the past few years. In contrast, the appealing aspects of allotransplant include the potential for a potent immune-mediated GVL effect which can reduce relapse rates and improve long-term LFS. Allografting using either related, URD or UCB early in the disease course could provide unique opportunities for improved survival.
Allogeneic transplantation for ALL
Allogeneic sibling donor HCT Since 2000, at least 10 trials have compared outcomes of patients with ALL with high-risk features based upon biologic assignment (related donor availability). [1] [2] [3] [4] We reviewed the prospective and retrospective series including over 40 patients in each arm. [5] [6] [7] [8] [9] [10] [11] Patients with high-risk ALL and an available HLA-matched sibling were offered myeloablative therapy and allogeneic sibling HCT in the first CR and compared to patients in 'no sibling donor group,' who received autologous HCT or other treatments. A total of 7 out of 10 studies demonstrated statistically significant improvement in LFS with allografts (range 34-72%) compared to 26-44% after autografting and OS of 37-75% vs 12-58%. (Table 1) . TRM varied considerably, between 9 and 29% and the highest reported 44% (LALA 87 trial 3 ) in sibling donor HCT compared to 2-24% in autografts.
Meta-analysis of all prospective trials (1274 patients) using this biologic assignment confirmed a beneficial effect of allogeneic sibling HCT. 13 Patients in the sibling donor group demonstrated better survival (risk of death without HCT hazard ratio (HR) 1.25 (95% CI, 1.02-1.63)), which Labar et al.
5
Dombret et al. 4 Ringden et al. 6 Attal et al. 7 Ribera et al. 8 Takeuchi et al. 9 Hunault et al. 10 Gupta et al.
11
Rowe et al.
12
LALA 87 prospective 12 Following a twophased induction therapy, 91% of patients achieved CR. Those p50 years who had an HLA-compatible sibling were assigned to undergo allogeneic HCT and their outcomes were compared to all other patients, who were randomly assigned between autologous HCT and standard consolidation. A total of 1512 patients were analyzed. Rowe et al. 12 reported OS 5-year rates of 38% for all patients and 46% patients who achieved CR. Individuals with standard risk ALL (defined as PhÀ, low WBC and age o30 years) had the best OS 57% compared to 35% in the high-risk group (PhÀ, high WBC or age 430) and 25% in very highrisk group (Ph þ ALL). These data suggest that survival of adult ALL patients with standard risk features was superior following sibling donor HCT in CR1. The greatest benefit was apparent primarily in patients o30 years as higher TRM canceled out the benefit of less relapse in older patients.
From the same study, the outcome of 609 ALL patients revealed a grim outlook following the first recurrence.
14 In contrast to 5-year survival of 38% in newly diagnosed patients, 5-year survival following initial relapse was only 7% (95% CI ¼ 4-9%). Factors predicting a good outcome after salvage therapy were young age and longer duration of first CR. It is interesting that the choice of treatment during CR1 did not influence outcome after relapse although those studied had been prescribed sibling donor allografting in CR1 when possible. Because extended CR2 and prolonged LFS after initial relapse is unexpected, the most effective therapy to prevent recurrence is of critical importance.
Unrelated donor marrow/PBSC HCT
The donor of choice is a HLA-matched sibling; however, only one-third of patients have an available sibling donor. No prospective or randomized study has compared the alternatives; either URD or autologous grafts in adults. Some published analyses have used URD data before the widespread use of high-resolution HLA typing. Since the extent of HLA mismatch modulates the incidence and severity of GVHD and TRM, data from some earlier analyses of URD HCT need to be interpreted cautiously.
In a large retrospective analysis from the Center for International Bone Marrow Transplant Research (CIBMTR), outcomes and toxicities of 712 patients o50 years old in CR1 or CR2 were compared based upon type of transplant (517 URD, 195 auto). 15 TRM was significantly higher after matched URD transplantation (4278%) than after autotransplantation (20712%; P ¼ 0.004). Due to more frequent relapse with autograft (49712%) vs URD (1475%; Po0.001), 3-year diseasefree survival (DFS) was similar after URD and autologous HCT (5177 vs 44712%). The long-term update of this analysis (CIBMTR) confirmed similar 5-year survival for patients in CR1 after URD HCT and auto-HCT (38 vs 39%), but superior 5-year survival after URD HCT in CR2 (30 vs 14%). Relapse rates for URD graft were 20% (CR1) and 25% (XCR2); substantially less than autologous transplant (CR1 58%, XCR2 81%; Po0.0001). Figure 1 shows survival comparing URD and autologous HCT in three prognostic groups. 16 Cornelissen et al. 24 analyzed NMDP data and reported the outcome of 127 adults with poor risk ALL who received a matched or single antigen mismatched URD HCT. Graft rejection occurred in 6% of patients. TRM was high at 54% and 27% of patients survived leukemia free at 2 years post-HCT. Significant risk factors for increased TRM were HLA-mismatched donor (relative risk (RR), 1.76; P ¼ 0.02), refractory leukemia (RR, 2.85; Po0.0001) and longer interval from diagnosis to HCT (RR, 1.33; P ¼ 0.008).
Philadelphia chromosome positive ALL
Patients with very high-risk ALL, including Ph þ ALL or recurrent leukemia are not salvaged with either standard chemotherapy or autologous HCT. However, the antileukemia effect of a donor graft can provide the potential to overcome the disease. Currently, for Ph þ ALL patients lacking available matched sibling donor URD HCT is recommended in CR1 or any later CR. In 1997, 18 patients with Ph þ ALL allografted using URD marrow were reported by Sierra et al. 17 Only seven patients were in CR1 while seven had chemotherapy refractory or more advanced disease. Despite very highrisk features, 2-year LFS was 49%. Notably, 78% developed acute GVHD and 50% had extensive chronic GVHD.
A large series from Dombret et al. 4 incorporated molecular monitoring for breakpoint cluster region (BCR)/Abelson (Abl). Among 154 adult patients with Ph þ ALL, 62% achieved CR within 3 months. Patients received an HCT with either a sibling graft (n ¼ 56), matched URD (n ¼ 14) or autologous cells (n ¼ 43). Survival in sibling HCT and URD HCT were similar. (URD RR, 0.53; 95% CI, 0.25-1.16). Relapse was less frequent 50% (95% CI, 37-65) in the donor group compared to those with no donor 90% (95% CI, 76-97%) and 3-year LFS was 37% (95% CI, 24-49%) vs 12% (95% CI, 4-24). Survival was best in those needingp2 cycles to achieve CR and those with negative BCR/Abl at HCT.
Two series reported data on children and young adolescents with Ph þ ALL. Marks et al. 18 reported 15 young patients with Ph þ ALL treated with T-cell depleted URD HCT. A 40% relapse rate and 2-year LFS of 49% was observed. Talano et al. 19 transplanted 29 patients using either an URD (n ¼ 23) or a mismatched family member (n ¼ 6). All patients engrafted. Grade III-IV acute and chronic GVHD developed in three and four patients, respectively, and event-free survival (EFS) at 10 years was 46%. Only two patients (7%) relapsed. Five of six patients died if beyond CR2 or in relapse at the time of transplant.
Based upon the poor prognosis of Ph þ ALL, alternative donor availability needs to be sought early in the course of disease. Incorporation of imatinib, dasatinib or monoclonal antibodies into treatment may be promising to increase the frequency of pre-transplant molecular remissions and may be valuable as post-HCT maintenance therapy. 20, 21 Evidence suggests that autologous HCT for Ph þ ALL is less successful, especially if minimal residual disease is present. Further validation of this approach incorporating molecular monitoring, tyrosine kinase inhibitors as well as other new and more effective therapy is needed.
PBSC or BM from an HLA-matched unrelated donor Garderet et al. 22 studied the outcome of HCT for patients with advanced ALL. Only 19% of patients were in CR1 and the majority were beyond CR2. They studied 102 patients with AML and ALL URD comparing URD using marrow vs PBSC. Acute GVHD occurred in 74% with PBSC compared to 54% with BM. There were no differences in TRM (61 vs 47%) or relapse rate (47 vs 39%). A total of 2-year survival was decreased in PBSC recipients (24 vs 32%; P ¼ 0.04). No other comparative data have been reported.
Matched unrelated donor vs sibling HCT
Two recent studies compared outcomes of matched URD and sibling allogeneic transplantation. Since HLA class I and II high-resolution HLA typing was used for most of these patients, this study results reflect more closely the current standard of donor selection. Kiehl et al. 23 reported results of 221 high risk or very high-risk adult ALL patients who received allogeneic HCT using either sibling (n ¼ 103) or URD (n ¼ 118). (Table 2 ) TRM was 43 and 50%. A 5-year DFS was similar (42% for sibling and 45% for URD) for patients transplanted in CR1. In contrast, DFS for patients in CR2 was improved only with sibling HCT (40%) but not with URD (17%; P ¼ 0.1). LFS was a median 10.4 months (sibling donor) and 6.0 months URD (P ¼ 0.015). In multivariate analysis, favorable DFS was demonstrated for TBI-based conditioning (RR, 0.79; 95% CI, 0.64-0.97), CR at transplant (RR, 0.73; 95% CI, 0.61-0.87) and marrow as a stem cell source (RR, 0.82; 95% CI, 0.69-0.98). The most important finding of this study is that DFS for adults with high-risk ALL in CR1 is similar between sibling and matched URD HCT.
In a second study Dahlke et al. 25 reported 84 consecutive high-risk ALL patients who received allogeneic sibling (n ¼ 46) or URD (n ¼ 38) grafts. A total of 3-year survival was 46 and 44%, respectively. Patient age o18 years and patient/donor sex mismatch were associated with improved OS. No relevant differences were found in TRM rate (27% and 26%).
These recent reports have addressed the therapeutic dilemma of high-risk ALL. TRM and more importantly OS of well-matched URD HCT were comparable to sibling HCT. Large and prospective trials, which would include high-resolution HLA matching and up-to-date supportive care are warranted to clarify any additional distinctions in risks or required patient support to yield these promising outcomes.
Decreasing treatment-related mortality
Except for suggestive data from a few clinical trials, the accepted indications for matched URD allogeneic HCT for ALL include Ph þ ALL and other high-risk cytogenetics plus very high WBC; delay in achieving CR1 and after initial relapse. High rate of early deaths from complications such as graft failure, acute GVHD and opportunistic infections reflect clinical reluctance to undertake URD HCT in standard risk patients in CR1. Several approaches are being studied to decrease treatment-related non-relapse mortality after HCT (Table 3) .
Role of conditioning-TBI and etoposide
To evaluate the utility of TBI in allogeneic transplantation for ALL, 43 patients under 21 years were randomized between TBI/Cy/etoposide (n ¼ 22) and Bu/Cy/etoposide (n ¼ 21). 33 There was no significant difference in EFS between Bu and TBI for patients who received sibling donor grafts (36 vs 58%, P ¼ 0.3). However, for URD, EFS was 20% for Bu and 57% for TBI (P ¼ 0.04). Relapses were similar in both arms. In another study, TBI improved DFS by reducing the relapse rate, possibly due to its effect in sanctuary sites of ALL. 26 Cy (B120 mg/kg) and TBI (B12 Gy) has been regarded as the standard regimen for ALL allografting for past 30 years. Marks et al. 27 compared
Cy/TBI to TBI/etoposide (60 mg/kg) in 502 patients with ALL reported to CIBMTR. Relapse, treatment failure and mortality were lower with etoposide/TBI, regardless of TBI dose (P ¼ 0.001). If Cy was used, OS was significantly improved with TBI doses p13 Gy (P ¼ 0.0005). Thus, both the chemotherapy agents used and the irradiation dose may interact in altering outcome.
Reduced intensity regimens
Reducing the conditioning regimen intensity prior to allotransplantation could decrease toxicity, while allowing engraftment and the subsequent GVL effect. In addition, the pool of eligible patients can be increased to include elderly patients and those with pre-HCT co-morbidities.
Arnold et al. 28 demonstrated the feasibility and safety of reduced intensity conditioning (RIC) for very high-risk adult ALL patients. Among 22 patients with advanced disease or Ph þ ALL, four (18%) were alive in CR 5, 14, 19 and 30 months after RIC HCT. Martino et al. 29 reported results of 27 adults ALL patients, 85% were beyond CR1, 44% were chemorefractory. The graft source was a matched URD or mismatched related donor in 44%. TRM was 23% (95% CI, 11-46%) and OS at 2 years was 31% (95% CI, 12-48%). A total of 49% patients developed recurrent leukemia (95% CI, 33-72%).
A study from Germany reported 25 adult patients with acute leukemia comparing RIC to a historical control (n ¼ 50) of patients after standard HCT. 34 A total of 36% patients had ALL, and over 30% of patients were older than 50 years. The RIC contained fludarabine/Bu and antithymocyte globulin. A 3-year LFS for ALL was 51 vs 46% (NS) as a result of very low TRM with the reduced intensity HCT (4 vs 28%; P ¼ 0.0029), despite a substan- Cornelissen et al. 24 Sierra et al. 17 Dombret et al. 4 Garderet et al. 22 Kiehl et al. 23 Dahlke et al. Consistent with these results, a study from Japan reported 33 patients with ALL transplanted with nonmyeloablative conditioning. 35 At 1-year DFS and OS were 30 and 39%, respectively. The estimated 3-year relapse rate was 51%. These results suggest that RIC HCT can reduce the risks of TRM and has promising efficacy in prolonging survival in some patients with high-risk ALL. Since the incidence of GVHD and opportunistic infections was not significantly altered in these early reports using RIC transplantation, longer follow-up is necessary to assess its comparative value. Future studies will help to establish the optimal regimens and identify the best patients with ALL to receive RIC HCT.
Umbilical cord blood HCT for adult ALL UCB transplantation is now a standard option for management of pediatric leukemia. Several series have reported equivalent outcomes to HLA-matched URD, although neutrophil recovery is significantly slower and less assured following UCB HCT. 36 Growing experience identified some unique differences between UCB and adult donor grafts. The high-proliferative potential of UCB stem cells and progenitors allows use of a UCB cell dose nearly 10 times lower than generally used in marrow transplants (2.5 Â 10 7 nucleated cells per kg vs 20-25 Â 10 7 per kg). The immune system of the newborn and consequently that from UCB is naı¨ve. UCB grafts in contrast to adult BM are permissive of the use of partially HLA-matched units without excessive graft rejection or severe GVHD. With partially mismatched UCB grafts, satisfactory outcomes have been reported and thus the donor pool can be expanded to ethnic or racial minority patients with uncommon HLA haplotypes, who have no suitably matched URD. This apparent immune tolerance accompanying UCB grafts has been associated with a reduced incidence of severe GVHD. Since collection of UCB is possible with every healthy delivery, the UCB donor supply is potentially unlimited as donation is uncomplicated and causes no harm to either the baby or the mother. UCB units are pre-screened for infections, HLA-typed and cryopreserved and are thus quickly available for a potential patient.
UCB donor transplant for acute leukemia
Several of Phase II series analyzed UCB allotransplant in diverse populations of patients, though only a minority had ALL. The results are confounded by the heterogeneity of remission status and variability in UCB cell dose and HLA matching. [37] [38] [39] Reported series to date in large part also reflect the multi-institutional learning curve in UCB graft selection and recipient supportive care.
Adult ALL patients were included in two largest multiinstitutional analysis comparing single unit UCB with volunteer URD HCT (Table 4) . Laughlin et al. 39 reporting for the International Bone Marrow Transplant Registry/ New York Blood Center (IBMTR/NYBC), included 40 out of 150 UCB recipients with ALL. 40 Outcomes were compared to URD (n ¼ 367, ALL n ¼ 82). In the UCB Table 4 Umbilical cord blood HCT which included patients with ALL Laughlin et al. 40 Rocha et al. 41 Takahashi et al. 42 Hahn et al. 58 Kumar et al. 43 Barker et al. 32 Lekakis et al.
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Cornelisen et al. Unrelated allotransplantation for adult ALL V Bachanova and D Weisdorf cohort, a greater proportion of patients were younger, weighed less and had advanced disease. All UCB grafts were one or two HLA-antigen mismatched. At 3 years, the median OS with UCB was 26% (95% CI, 19-32) and URD 35% (95% CI, 30-39). Outcomes of UCB and URD were not affected by type of underlying malignancy (P ¼ 0.61).
The risk of acute GVHD in UCB transplants was greater than in matched URD (HR, 1.62; 95% CI, 1.08-2.42).
In a second major report, Rocha et al. 41 analyzed a European Blood and Marrow Transplant Group (EBMT) and Eurocord dataset of 98 UCB transplants, 53 with ALL. 41 Outcomes were compared to 584 URD marrow transplants (ALL, n ¼ 267). UCB recipients more often had advanced leukemia (Po0.002) and had received prior autografts (Po0.001). Non-engraftment was observed in 20% of UCB and 7% URD transplants. However, 2-year LFS in ALL was 34% (UCB) and 33% (URD; P ¼ 0.21). Relapse and TRM were similar in both groups (Table 4) . Despite greater HLA mismatch with UCB, the cumulative incidence of acute GVHD was significantly lower in the UCB cohort (26% (95% CI, 14-38) vs 39% (31-47)).
Eurocord recently reported an updated analysis of 171 patients transplanted after 1997; 35% of patients had ALL. At 2 years, LFS for patients transplanted with early, intermediate or advanced disease was 41, 34 and 18 months, respectively. The 2-year cumulative incidence of TRM and relapse were 51% and 22%. Takahashi et al. 42 compared UCB HCT (n ¼ 68, ALL ¼ 15) with URD HCT (n ¼ 45, ALL ¼ 8). Five receiving UCB (8%) did not engraft. At a median follow-up of 14 months, OS, TRM and relapse were superior for UCB vs URD HCT (74 vs 44%; 9 vs 29%; 16 vs 25%, respectively). These surprising good results are not fully explained since discrepancies in efficacy could result from heterogeneity of the comparative cohorts. Nonetheless, these results with UCB grafting are encouraging.
A recent meta-analysis objectively analyzed pooled data from these three comparative studies. 44 Overall, 316 adults undergoing UCB transplant were compared to 996 adults undergoing mostly fully matched URD HCT for different hematological malignancies. The estimated DFS was similar with either donor source (UCB RR, 0.59; 95% CI, 0.18-1.96). These results highlight that mismatched UCB grafts can be as successful as fully matched URD for allotransplantation without increased risks of either GVH or TRM (RR, 1.04; 95% CI, 0.42-5.03). More refined data for patients with ALL are needed.
UCB allotransplantation for ALL at the University of Minnesota Kumar et al. 43 presented the initial experience of UCB HCT for patients with high-risk ALL to evaluate the relative efficacy of donor source on outcomes following myeloablative HCT. A total of 138 adults aged 18-61 (median 31) years underwent allogeneic HCT using UCB (n ¼ 19) sibling donor (n ¼ 90), matched URD (n ¼ 15) and mismatched URD (n ¼ 14). At the time of HCT, 92% were in CR1 or CR2. Superior 3-year survival in the UCB group (61% (95% CI, 44-89%)) compared to 27% (95% CI, 17-36%) in the sibling and 13% (95% CI, 0-31%) in the URD group suggested the efficacy of UCB graft HCT for ALL. Perhaps the most promising finding is the low relapse rate at 3 years (5% (95% CI, 0-15%)) in the UCB group compared to 26% (95% CI, 16-35%) and 20% (95% CI, 1-39%) in the sibling and URD groups, respectively. TRM at 3 years was the 34% (95% CI, 12-56%) in the UCB group, but was higher in the other donor groups: sibling 44% (95% CI, 24-55%), URD 53% (95% CI, 27-80%) and unacceptably high in mismatched URD 86% (95% CI, 57-100%). The development of GVHD correlated with improved LFS (RR, 0.4; 95% CI, 0.2-0.6, Po0.01), consistent with strong GVL effect using all donor sources.
A recent analysis described 623 consecutive patients with ALL treated at University of Minnesota from 1980 to 2005. 45 All patients received myeloablative, TBI-containing conditioning (TBI, 1320-1375 cGy) and either autologous HCT (34%), sibling (45%), URD (16%) or UCB HCT (11%). Disease status at transplant was CR1 (24%), CR2 (50%), CR3 (18%) and relapse (8%). The median followup was 8.3 years. A 5-year OS of UCB patients (46%, 95% CI, 33-59%) was comparable to sibling grafts (35%, 95% CI, 29-41%), and matched unrelated grafts (42%, 95% CI, 29-55%), while mismatched unrelated grafts yield inferior survival (21%, 95% CI, 11-33%). Multivariate adjusted risks of TRM, 5-year relapse and DFS were comparable between UCB and sibling transplants (UCB RR, 1.7 (0.9-3.2); RR, 0.6 (0.4-1.0); RR, 0.8 (0.5-1.1), respectively). Acute GVHD was more frequent with URD (P ¼ 0.01), but similar for sibling donors and UCB. These encouraging results suggest that use of UCB grafts in therapy of adult ALL could be a suitable and similarly effective alternative to an HLA-matched sibling or URD for HCT.
Improving UCB allotransplantation for ALL Double UCB units for HCT Experience with single unit UCB transplant has suggested that a suitable cell dose (2.5 Â 10 7 cells per kg) is a critical determinant of good outcome 46 Pioneering experience from the University of Minnesota offered a successful strategy to overcome the limitations of cell dose, particularly for adults and larger individuals. Initially in a case report 47 and subsequently in a series of 23 patients with advanced leukemia (ALL: n ¼ 8), we described use of two partially HLA-matched UCB units to provide an adequate CD34 þ and hematopoietic stem cell dose 32 All patients engrafted at a median time of 23 days. By day þ 100, a single UCB unit predominated in each patient. Despite advanced disease in this initial group of patients, DFS was 57% (95% CI, 35-79%) at 1 year.
We further observed that the use of double unit UCB grafts may be associated with a reduced risk of relapse in children with acute leukemia in first or second CR. 48 All patients (n ¼ 96) received the recommended cell dose 42.5 Â 10 7 per kg. With a minimum follow-up of 1 year, in adjusted multivariate analysis, the RR of leukemia relapse was reduced to 0.3 with double UCB compared to single UCB (P ¼ 0.03). Overall risk of relapse was 11% (95% CI, 0-25%) in those patients receiving double unit vs 54% (95% CI, 23-85%) for single UCB (Po0.01) in both AML as well as ALL. Although most UCB grafts have up to two HLA antigen mismatches, some data suggest that more stringent HLA matching could improve GVHD, reduce TRM and improve OS. 36, 49 The effect of better matching on protection of relapse is less certain.
Several series reported safety and efficacy of double UCB transplantation in variety of hematological malignancies using both myeloablative and non-myeloablative conditioning. Due to small patient numbers, data for ALL are not reported. [50] [51] [52] [53] Procedural and clinical principles of multiple unit UCB HCT were recently reviewed. 54 These data suggest that UCB transplantation is a safe, effective and accepted treatment alternative for adult patients with high-risk ALL. In contrast to adult donor grafts, the limited cell dose may be overcome by using two UCB units. While the unavailability of donor lymphocytes (DLI) for therapy of relapse after UCB HCT has been cited as a drawback, the efficacy of DLI in relapsed ALL is only modest and thus may be of little importance. The selection of UCB vs a well-matched URD is still controversial but offers increasingly broad and promising options to patients in need of an allograft.
Choosing the optimal donor for the ALL patient
In the absence of sibling donor, the choice between a wellmatched URD adult and a UCB graft needs to be carefully considered for high-risk patients based upon the patient's weight, HLA phenotype, the aggressiveness and pace of their ALL as well as on the experience of their transplant center. Currently the best URD is an allele matched with the recipient at HLA-A, B, C and DR. 55 In a retrospective analysis of over 3800 donor-recipient pairs, Lee et al. 56 confirmed that absence of HLA-DQ matching did not adversely affected outcome following unrelated marrow transplantation. Nevertheless, partially mismatched URD donors compromise engraftment, GVHD risks and survival. With 12 000 000 donors available in registries, an 8/8 allele match is found for over 75% of Caucasians; however, for ethnic and racial minorities only 24-48% find wellmatched donor. 57 Volunteer donor registries including NMDP had launched several programs to increase donor diversity. Identification, screening and logistics of donor collection most often requires 8-12 weeks though expedited search and collection procedures are available for urgent HCT.
UCB grafts mismatched at 0-2 HLA loci with adequate cell dose are a good alternative to matched URD for children and young adults with high-risk ALL. When only partially matched URDs are identified, UCB grafts of adequate cell dose may be preferred. UCB grafts may be particularly appealing for patients in ALL where the risk of relapse is imminent and only a brief CR is expected. Additionally, patients with detectable minimal residual disease or evidence of subclinical molecular relapse have only a short window of opportunity to undergo transplantation. Since approximately 250 000 U are cryopreserved available worldwide and require only HLA type confirmation and transport to the transplant center, UCB grafts may permit urgent transplantation prior to another relapse and thereby reduce the patients' morbidity and risks of treatment.
Conclusions
Growing clinical experience using allotransplantation including URD and UCB donors offers greater hope for more patients with adult ALL. Recent research focuses on refining the ALL risk categories applying molecular analysis and genetics, designing induction regimens which incorporate new agents, tyrosine kinase inhibitors and monoclonal antibodies. Monitoring of minimal residual disease and disease control prior to HCT appears to be important for outcome following HCT. Furthermore, the role of RIC, new immunosuppressive agents to prevent GVHD and ways to enhance GVL effect with biological response modifiers all are exciting fields in era of immunomodulation to improve survival. Broader availability of UCB grafts will be possible with expansion of UCB banks. Incorporating ALL-HCT into well-designed clinical trials is of the critical importance. The optimal sequence of therapeutic steps may change in the future, yet the adherence to current evidence and knowledge may lead to improved survival of adult ALL patients.
